JP2010522227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522227A5 JP2010522227A5 JP2010500344A JP2010500344A JP2010522227A5 JP 2010522227 A5 JP2010522227 A5 JP 2010522227A5 JP 2010500344 A JP2010500344 A JP 2010500344A JP 2010500344 A JP2010500344 A JP 2010500344A JP 2010522227 A5 JP2010522227 A5 JP 2010522227A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- HCXBYIHIMJUDJQ-YUMQZZPRSA-N (1s,3s)-1-(aminomethyl)-3-methylcyclohexan-1-ol Chemical compound C[C@H]1CCC[C@@](O)(CN)C1 HCXBYIHIMJUDJQ-YUMQZZPRSA-N 0.000 claims 1
- OGZOWUDUUFGSIY-UHFFFAOYSA-N 2,6-dichloro-5-iodoquinoline Chemical compound IC1=C(Cl)C=CC2=NC(Cl)=CC=C21 OGZOWUDUUFGSIY-UHFFFAOYSA-N 0.000 claims 1
- HDDHLRKCWLHXTN-OPILKIMUSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-(3-hydroxy-3-methylpyrrolidin-1-yl)quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3CC(C)(O)CC3)=CC=C12 HDDHLRKCWLHXTN-OPILKIMUSA-N 0.000 claims 1
- BAHOQKHEWZJWME-WNSKOXEYSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-(4-hydroxypiperidin-1-yl)quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3CCC(O)CC3)=CC=C12 BAHOQKHEWZJWME-WNSKOXEYSA-N 0.000 claims 1
- GTFTZKPCYSYNOU-KIMHZCHSSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-[(3r)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3C[C@H](O)CC3)=CC=C12 GTFTZKPCYSYNOU-KIMHZCHSSA-N 0.000 claims 1
- GTFTZKPCYSYNOU-DFFLPILJSA-N 6-chloro-n-[[(1s,3s)-1-hydroxy-3-methylcyclohexyl]methyl]-2-[(3s)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide Chemical compound C1[C@@H](C)CCC[C@@]1(O)CNC(=O)C1=C(Cl)C=CC2=NC(N3C[C@@H](O)CC3)=CC=C12 GTFTZKPCYSYNOU-DFFLPILJSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- BURJIEWNHIKROD-FWDYTFEUSA-N [[(2r,3r,4r,5s)-5-(6-aminopurin-9-yl)-4,5-dibenzoyl-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C([C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@]1(N1C=2N=CN=C(C=2N=C1)N)C(=O)C=1C=CC=CC=1)C1=CC=CC=C1 BURJIEWNHIKROD-FWDYTFEUSA-N 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89629807P | 2007-03-22 | 2007-03-22 | |
| PCT/GB2008/000946 WO2008114002A1 (en) | 2007-03-22 | 2008-03-19 | Quinoline derivatives for the treatment of inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522227A JP2010522227A (ja) | 2010-07-01 |
| JP2010522227A5 true JP2010522227A5 (enExample) | 2011-04-07 |
Family
ID=39471999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010500344A Pending JP2010522227A (ja) | 2007-03-22 | 2008-03-19 | 炎症性疾患の処置のためのキノリン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7964616B2 (enExample) |
| EP (1) | EP2139879B1 (enExample) |
| JP (1) | JP2010522227A (enExample) |
| KR (1) | KR20090122396A (enExample) |
| CN (1) | CN101679350B (enExample) |
| AR (1) | AR065806A1 (enExample) |
| AU (1) | AU2008228067B2 (enExample) |
| BR (1) | BRPI0809106A2 (enExample) |
| CA (1) | CA2680761A1 (enExample) |
| CL (1) | CL2008000825A1 (enExample) |
| ES (1) | ES2388454T3 (enExample) |
| MX (1) | MX2009010059A (enExample) |
| PE (1) | PE20091225A1 (enExample) |
| RU (1) | RU2460727C2 (enExample) |
| TW (1) | TW200904427A (enExample) |
| UY (1) | UY30976A1 (enExample) |
| WO (1) | WO2008114002A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008114002A1 (en) | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Quinoline derivatives for the treatment of inflammatory diseases |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
| KR101995088B1 (ko) | 2011-07-22 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| NZ628910A (en) | 2012-01-20 | 2016-02-26 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| PL2931717T3 (pl) | 2012-12-12 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Pochodne indolokarboksyamidu jako antagoniści receptora p2x7 |
| US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
| WO2014115078A1 (en) | 2013-01-22 | 2014-07-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| KR102222220B1 (ko) | 2013-01-22 | 2021-03-03 | 이도르시아 파마슈티컬스 리미티드 | Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
| TWI624467B (zh) * | 2013-10-14 | 2018-05-21 | 衛材Ｒ＆Ｄ企管股份有限公司 | 選擇性經取代之喹啉化合物 |
| AU2015269598B2 (en) * | 2014-06-05 | 2019-11-14 | Merck Patent Gmbh | Novel quinoline derivatives and their use in neurodegenerative diseases |
| ES2928164T3 (es) | 2015-10-19 | 2022-11-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| MY199705A (en) | 2015-12-22 | 2023-11-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| KR102685249B1 (ko) | 2016-06-20 | 2024-07-17 | 인사이트 코포레이션 | 면역조절제로서의 복소환식 화합물 |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| CA3047991A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| RS64055B1 (sr) | 2018-03-30 | 2023-04-28 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| MD3790877T2 (ro) | 2018-05-11 | 2023-08-31 | Incyte Corp | Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1 |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
| PE20230407A1 (es) | 2019-11-11 | 2023-03-07 | Incyte Corp | Sales y formas cristalinas de un inhibidor de pd-1/pd-l1 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| TW202233616A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3352912A (en) | 1963-07-24 | 1967-11-14 | Du Pont | Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes |
| US3471491A (en) | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| GB1274652A (en) | 1968-08-27 | 1972-05-17 | Lilly Industries Ltd | Adamantanyl-alkylamine derivatives and their preparation |
| IL53441A0 (en) | 1977-11-22 | 1978-01-31 | Teva Pharma | Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them |
| FR2582514B1 (fr) * | 1985-05-30 | 1988-02-19 | Rhone Poulenc Sante | Medicaments a base d'amides, nouveaux amides et leur preparation |
| US4751292A (en) | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| ATE148098T1 (de) | 1991-02-21 | 1997-02-15 | Sankyo Co | Benzolderivate zum fördern der produktion des nervenwachstumsfaktors |
| PT720601E (pt) | 1993-08-10 | 2001-02-28 | Black James Foundation | Ligandos de receptores de gastrina e cck |
| RO114445B1 (ro) | 1994-05-27 | 1999-04-30 | Smithkline Beecham S.P.A. | Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament |
| AR004735A1 (es) | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
| NZ332341A (en) | 1996-05-20 | 2000-05-26 | Darwin Discovery Ltd | Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors |
| FR2761358B1 (fr) | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO1999026927A2 (en) | 1997-11-21 | 1999-06-03 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| HUP0202214A3 (en) | 1999-04-09 | 2002-12-28 | Astrazeneca Ab | Adamantane derivatives, preparation and use thereof |
| CN1361768A (zh) | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
| WO2001037826A1 (en) | 1999-11-26 | 2001-05-31 | Shionogi & Co., Ltd. | Npyy5 antagonists |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| RU2347570C2 (ru) | 2001-07-02 | 2009-02-27 | Н.В.Органон | Тетрагидрохинолиновые производные |
| WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
| SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| AU2003226149A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
| ES2281801T3 (es) * | 2003-05-12 | 2007-10-01 | Pfizer Products Inc. | Inhibidores benzamida del receptor p2x7. |
| GB0312609D0 (en) * | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| US20080058309A1 (en) | 2006-07-27 | 2008-03-06 | Astrazeneca Ab | Novel Compounds 171 |
| WO2008114002A1 (en) | 2007-03-22 | 2008-09-25 | Astrazeneca Ab | Quinoline derivatives for the treatment of inflammatory diseases |
| US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
-
2008
- 2008-03-19 WO PCT/GB2008/000946 patent/WO2008114002A1/en not_active Ceased
- 2008-03-19 RU RU2009135621/04A patent/RU2460727C2/ru not_active IP Right Cessation
- 2008-03-19 BR BRPI0809106-4A patent/BRPI0809106A2/pt not_active IP Right Cessation
- 2008-03-19 CA CA002680761A patent/CA2680761A1/en not_active Abandoned
- 2008-03-19 PE PE2008000516A patent/PE20091225A1/es not_active Application Discontinuation
- 2008-03-19 AR ARP080101169A patent/AR065806A1/es unknown
- 2008-03-19 AU AU2008228067A patent/AU2008228067B2/en not_active Ceased
- 2008-03-19 EP EP08718785A patent/EP2139879B1/en not_active Not-in-force
- 2008-03-19 JP JP2010500344A patent/JP2010522227A/ja active Pending
- 2008-03-19 MX MX2009010059A patent/MX2009010059A/es active IP Right Grant
- 2008-03-19 KR KR1020097021940A patent/KR20090122396A/ko not_active Ceased
- 2008-03-19 CN CN200880017135.1A patent/CN101679350B/zh not_active Expired - Fee Related
- 2008-03-19 ES ES08718785T patent/ES2388454T3/es active Active
- 2008-03-20 CL CL2008000825A patent/CL2008000825A1/es unknown
- 2008-03-21 US US12/052,908 patent/US7964616B2/en not_active Expired - Fee Related
- 2008-03-21 TW TW097110021A patent/TW200904427A/zh unknown
- 2008-03-24 UY UY30976A patent/UY30976A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230024173A1 (en) | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors | |
| EP3873462A1 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| RU2009135621A (ru) | Хинолиновые производные для лечения воспалительных заболеваний | |
| JP2021517132A (ja) | ４’−ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| CA3130210A1 (en) | Cyclin-dependent kinase 2 biomarkers and uses thereof | |
| WO2022174194A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| CN114867351B (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| TW201605452A (zh) | 以嘧啶化合物作爲有效成分之醫藥組成物 | |
| TW201542581A (zh) | 核苷酸與核苷治療組成物及其相關用途 | |
| JP2007302689A5 (enExample) | ||
| JP2008533007A5 (enExample) | ||
| JP2017511377A5 (enExample) | ||
| JP2012519182A5 (enExample) | ||
| US20240100018A1 (en) | Compounds for the treatment of a disease or disorder, methods for identifying said compounds | |
| JP2011505356A5 (enExample) | ||
| JP2022548907A (ja) | ベンズイミダゾールおよびそれを使用する方法 | |
| JP2022106920A (ja) | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 | |
| JP2011520853A5 (enExample) | ||
| France et al. | Synthetic approaches to the new drugs approved during 2022 | |
| JP2011509306A5 (enExample) | ||
| US20110104186A1 (en) | Small molecule immunopotentiators and assays for their detection | |
| JP2010500284A5 (enExample) | ||
| JP2010510263A5 (enExample) | ||
| EP3648764A2 (en) | Treatment of cancer with dihydropyridines | |
| JP2010540422A5 (enExample) |